ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Diagnostic utility of multiparametric flow cytometric immunophenotyping in myelodysplastic neoplasms].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiparameter flow cytometry (MFC) has proven its value as a complementary diagnostic tool for myelodysplastic neoplasms (MDS). It is almost universally adopted in everyday clinical practice for assessing patients with cytopenia and suspected MDS through simplified scoring systems or elaborate analytical strategies for detecting immunophenotypical dysplastic features in every hematopoietic cell lineage in the bone marrow (BM). Current guidelines recommend flow cytometric analysis as part of the diagnostic assessment of patients with cytopenia suspected of MDS. We reviewed the existing knowledge and recent advances in the field concerning ①the optimal methods of sample processing and handling, ②antibody panels and fluorochromes, ③the analysis of several BM cell subsets, such as myeloid precursors, maturing granulocytic and monocytic components, and erythropoiesis, and ④MFC scoring systems for immunophenotypic signs of myelodysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.